Nectar Life sciences Ltd, a US$ 200 million organisation, with a strong presence in anti-bacterial segment of global pharma, particularly Cephalosporins, has initiated a long term supply of its innovation molecule bulk drug (API) Cefuroxime Axetil, to the world's second largest innovator pharmaceutical company, GlaxoSmithKline.
The details can be read here.
No comments:
Post a Comment